Press Releases
// Mar 10, 2025
ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI
// Feb 24, 2025
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease
// Jan 09, 2025
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
// Nov 04, 2024
ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development
// Oct 16, 2024
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential
// May 14, 2024
ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques
// Apr 22, 2024
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
// Jan 08, 2024
ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference
// Sep 26, 2023
Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing
// May 24, 2023
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth
// May 24, 2023
Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases
// May 15, 2023
